Pregnant with metastatic neuroendocrine tumour of the ovary: What now?

B. Pistilli, C. M. Grana, N. Fazio, A. Cavaliere, M. E. Ferrari, L. Bodei, S. M. Baio, G. Scambia, G. Paganelli, Fedro A. Peccatori

Research output: Contribution to journalArticlepeer-review


Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms commonly occurring in the gastrointestinal tract or lungs but can occur in other regions. Primary ovarian NET account for 5% of all NET and 0.1% of all ovarian malignancies. In metastatic disease, the therapeutic goal is to extend survival and to improve quality of life. As these tumours express somatostatin receptors, somatostatin analogues are frequently used to control symptoms. Here we present a case of a pregnant woman with an ovarian NET with liver metastases and carcinoid syndrome who was treated with the somatostatin analogue, Octreotide LAR. We also summarize reported data of the use of somatostatin analogues during pregnancy. Copyright:

Original languageEnglish
Article number240
Issue number1
Publication statusPublished - Jan 3 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Pregnant with metastatic neuroendocrine tumour of the ovary: What now?'. Together they form a unique fingerprint.

Cite this